Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2018-04-23 Director's Dealing
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
DGAP-DD: BB BIOTECH AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It lists the name of the associated person (Klaus Strein, Member of the administrative or supervisory body), the nature of the transaction ('Acquisition'), the price, volume, and date. This content directly matches the definition for Director's Dealing.
2018-04-23 English
BB Biotech share gains value in first quarter 2018 - several large-cap biotech companies trading at well below fundamental value
Report Publication Announcement Classification · 95% confidence The document is an announcement titled 'Interim report of BB Biotech AG as of March 31, 2018'. While it provides a summary of financial performance, portfolio activity, and outlook, it explicitly states at the end: 'The complete interim report as at March 31, 2018 is available on www.bbbiotech.com'. Following the 'Menu vs Meal' rule, because this document is an announcement directing the reader to the full report rather than being the full report itself, it is classified as a Report Publication Announcement (RPA). Q1 2018
2018-04-20 English
Q1 statement / Q1 financial report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter of 2018 (ending March 31, 2018). It includes a 'Letter to the shareholders', 'Consolidated interim financial statements', 'Selected explanatory notes', and detailed portfolio performance data. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2018
2018-04-20 German
BB BIOTECH AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.30
Notice of Dividend Amount Classification · 99% confidence The document text explicitly mentions 'Shareholders at the general meeting vote in favor of all proposals' and discusses the approval of a dividend following the 'Annual General Meeting'. This content directly relates to the proceedings and outcomes of an AGM. Although it mentions dividend approval (DIV) and board elections (MANG), the overarching context is the meeting itself. The most specific and encompassing category for materials related to the Annual General Meeting is AGM-R (AGM Information). The document is a news release summarizing the results, which is consistent with AGM-R materials.
2018-03-13 English
BB Biotech AG publishes its 2017 annual report (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "BB Biotech AG publishes its 2017 annual report (news with additional features)" and states, "BB Biotech AG published its annual report for fiscal year 2017 today." It contains key financial highlights (Total Share Return, NAV performance, consolidated net gain/loss) which are typical of an earnings release or the summary section of an annual report. However, the document itself is a short news release (indicated by the DGAP-News header and the structure) whose primary purpose is to announce the availability of the full annual report, which can be downloaded via a link. According to Rule #2 (The 'MENU VS MEAL' Rule), if the document is short and announces that a report has been published, it should be classified as a Report Publication Announcement (RPA). While it contains substantial financial data, its function here is the announcement/publication notice of the full 2017 Annual Report, not the comprehensive 10-K filing itself.
2018-02-16 English
Annual financial report 2017
Annual Report Classification · 100% confidence The document is a comprehensive annual report for BB Biotech for the fiscal year 2017. It includes a shareholder letter, detailed financial performance metrics, a multi-year comparison table, a table of contents listing consolidated financial statements, notes to the financial statements, auditor reports, corporate governance, and a remuneration report. The document length and content confirm it is the full annual report rather than a summary or announcement. FY 2017
2018-02-16 German

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.